l-carnitine for cancer patients Carnitine L-Carnitine Vitamin Supplement for Energy

repletion reverses hematologic symptoms within days and neurologic sequelae over weeks, reflecting differential tissue turnover

Clinical trials in patients with metabolic syndrome reveal that L-Carnitine supplementation of 2 g/day for extended periods (25-50 weeks) significantly reduces fasting blood glucose, HbA1c, homeostatic model assessment-insulin resistance (HOMA-IR), inflammatory markers including C-reactive protein (CRP) and tumor necrosis factor-alpha (TNF-), and triglyceride levels

Steps of the carnitine shuttle system Formation of Acyl-Carnitine: Long-chain fatty acids in the cytosol are activated to acyl-CoA, which then reacts with carnitine in the presence of CPT I to form acyl-carnitine

PMID: 39022677